The chloride/phosphate ratio combined with alkaline phosphatase as a valuable predictive marker for primary hyperparathyroidism in Chinese individuals

Qianqian Wang, Xu Li, Haibing Chen, Haoyong Yu, Lianxi Li, Jun Yin, Jian Zhou, Ming Li, Qing Li, Junfeng Han, Li Wei, Fang Liu, Yuqian Bao & Weiping Jia

The chloride/phosphate ratio (CI/PO4) has been suggested to have a role in primary hyperparathyroidism (PHPT), but the associations between CI/PO4 combined with ALP level and PHPT has not been well-studied. Our aim was to investigate the predictive value of combination CI/PO4 with ALP for PHPT. A cross-sectional retrospective analysis was conducted to examine 172 patients diagnosed with PHPT categorized into two groups: normocalcaemic primary hyperparathyroidism (NPHPT) group and hypercalcaemia PHPT group. We found that CI/PO4 levels and ALP levels in the NPHPT and hypercalcaemia PHPT group were both significantly higher than normal controls. CI/PO4 and ALP levels were an independent risk factor for PHPT. CI/PO4 combined with ALP increased the receiver-operating characteristic curves (ROC-AUC) and the diagnostic value in NPHPT and hypercalcaemia PHPT group (0.913; 95% CI, 0.744–1.000 and 0.932; 95% CI, 0.897–0.966, respectively), specificity of 92.8% and sensitivity of 98%. In conclusion, combination CI/PO4 with ALP level measurement have great potential to predict significant occurrence of NPHPT.

Primary hyperparathyroidism (PHPT) is characterised biochemically by an inappropriately elevated parathyroid hormone (PTH) level and it is one of the most common endocrine disorders affecting human health. Using the serum calcium level, PHPT can be subdivided into normocalcaemic primary hyperparathyroidism (NPHPT) and hypercalcaemic primary hyperparathyroidism. Wills first used the term NPHPT in the 1960s. NPHPT is characterised by normal serum calcium levels and consistently high PTH levels. NPHPT is not a common type of PHPT. Persistently elevated PTH and hypercalcaemia are the diagnostic markers of PHPT. Several studies have used the oral calcium load to diagnose PHPT in patients with NPHPT and asymptomatic patients. However, in clinical, we found PTH testing did not appear in the conventional inspection indicators, and the PTH testing equipment are expensive and time-consuming. And some Chinese remote areas had no equipment measuring PTH. To improve the diagnosis of PHPT, we need to find additional, simple markers for diagnosing PHPT.
Reeves introduced the concept of the chloride/phosphate ratio (Cl/PO4)\(^6\). Some studies found that Cl/PO4 was a good tool for distinguishing PHPT from other causes of hypercalcaemia\(^7\)-\(^10\). Furthermore, Mismar et al.\(^11\) reported that Cl/PO4 was predictive in normocalcaemic patients in an Indian population. Katelina\(^12\) and McComb\(^13\) et al. suggested that alkaline phosphatase (ALP) is a membrane-bound enzyme associated with the mineralization of bone tissue. The serum ALP level is elevated in 96% of patients with primary hyperparathyroidism\(^13\). But there have been no study evaluating predicting diagnostic value of Cl/PO4 combined with ALP in PHPT. Therefore, this study investigated the value of the two indicators combination measurement as an auxiliary diagnostic method for PHPT diagnosis in a Chinese population, especially for predicting significant occurrence of NPHPT.

Materials and Methods

Study Population. From January 2003 to March 2015, 172 patients with PHPT in the General Surgery Department of Shanghai Jiao Tong University Affiliated Sixth People's Hospital were enrolled in our study. According to Chinese guidelines, for PHPT definition we used as main criteria a PTH level >6.5 and the presence of parathyroid adenoma based on intraoperative frozen and postoperative pathology, but not calcium blood level. PHPT can be subdivided into NPHPT and hypercalcaemic primary hyperparathyroidism using the serum calcium level. The exclusion criteria were as follows: all PHPT patients treated without surgery; secondary hyperparathyroidism; vitamin D deficiency; renal disease; hypercalcuria caused by other diseases; the use of diuretics; liver disease and other causes of an elevated PTH. The subjects were divided into two groups according to the serum calcium levels: 151 had a high serum calcium and PTH, while 19 patients were defined as NPHPT. During the same period, 50 clinical check-up healthy subjects from medical examination center of Shanghai Jiao Tong University Affiliated Sixth People's Hospital were enrolled in our study. The inclusive criteria for them is as follows: All these participants had normal PTH levels, not suffering from PHPT disease, no family history of PHPT, normal renal function, and none were receiving medications known to influence these parameters such as sodium, potassium, ALP, phosphorus, chloride, calcium and PTH. The exclusion criteria of the control group is as follows: Patients were excluded if they had any disease that could affect electrolyte disorder (e.g. cancer, liver disease, cacoctrophy, renal insufficiency, hypovolaemia and dehydration). Participants with using any related drugs such as diuretics were also excluded from the study. The study was approved by the Human Research Ethics Committee of Shanghai Sixth People's Hospital, all experiments were performed in accordance with relevant guidelines and regulations. Each participant gave written informed consent.

Anthropometric evaluation and biochemical measurements. General information on the 222 participants, such as gender and age, was obtained through inquiry. Anthropometric parameters such as height, body weight, and blood pressure were measured and the Body Mass Index (BMI) was calculated as weight/height\(^2\). Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) were measured enzymatically on a Hitachi 7600 analyser (Hitachi, Tokyo, Japan). Serum sodium, potassium, alkaline phosphatase (ALP), phosphorus, chloride, and calcium were measured using automated techniques before surgery. ALP was detected by AMP buffer method of the ALP kit (KH-G-C-012) obtaining from Shanghai Kehua Bio-engineering Co., Ltd (Shanghai, China). The normal range for ALP is from 14 to 112 U/L. We calculated the chloride/phosphate ratio (Cl/PO4) as chloride (mEq/L)/phosphate (mg/100 mL). The total serum calcium levels used in our research was adjusted for albumin. The formula to use is: corrected calcium = measured total serum calcium in mg/dL + 0.8*(4.0 - patient's serum albumin concentration in g/dL). Serum PTH was measured by using an electrochemiluminescence immunoassay (ECLIA) on an Elecsys autoanalyser (E170; Roche Diagnostic, Mannheim, Germany). All biochemical values were measured from the same blood sample collected after an overnight fast. Related indicators were detected by Department of Medical Laboratory in Shanghai Jiao Tong University Affiliated Sixth People's Hospital. And the detection methods of related indicators had not changed.

Statistical analyses. Statistical analysis was performed using SPSS for Windows software (ver. 17.0; SPSS Inc., Chicago, IL, USA). Normally distributed data are presented as means ± standard deviation (SD). Non-normally distributed data determined using the Kolmogorov–Smirnov test are expressed as medians and interquartile range (25–75%). Two groups were compared using Student's unpaired t-test. The composition ratio of categorical variables was calculated using the chi-square test. Pearson's correlation was used to evaluate the association among the Cl/PO4 ratio, ALP and other general biochemical parameters. To analyse whether Cl/PO4 and ALP might be related to PHPT independently, we applied logistic regression models to adjust for other clinical and biochemical variables. The predictive performance of each model was assessed using the receiver operating characteristic (ROC-AUC) curve with 95% confidence intervals (CI). All P-values were two-tailed and statistical significance was considered as P < 0.05.

Results

Subject characteristics and Serum Cl/PO4 or ALP Levels at Baseline. Table 1 summarises the clinical characteristics of the study subjects with primary hyperparathyroidism (PHPT) and normal controls. PHPT was subdivided into normocalcaemic primary hyperparathyroidism (NPHPT) and hypercalcaemia groups according to the serum calcium level. In this cross-sectional analysis of NPHPT and normal controls, no significant differences in the proportion of males, BMI, diastolic blood pressure (DBP), ALT, AST, or potassium were observed. However, patients with NPHPT were older, and had higher systolic blood pressure (SBP), ALP [107.0 (74.0–269.0) vs. 61.5 (55.8–76.3), P < 0.001], PTH, sodium, calcium [2.6 (2.5–2.6) vs. 2.4 (2.3–2.4), P = 0.001] and Cl/PO4 levels [33.9 (31.7–43.0) vs. 29.9 (27.6–32.3), P = 0.002], and a lower haemoglobin (Hb) level (P < 0.001), than controls. After adjusting for age and sex in the NPHPT group, SBP (P = 0.118) and calcium (P = 0.094) lost significance. The hypercalcaemia group of PHPT was older (P < 0.01) than the normal controls,
but had a significantly (all \( P < 0.01 \)) smaller proportion of males and lower BMI, Hb, and ALT. Moreover, ALP [114.0 (79.5–289.5) vs. 61.5 (55.8–76.3), \( P < 0.001 \)], PTH, sodium, calcium, and Cl/PO₄ [43.1 (37.0–47.5) vs. 29.9 (27.6–32.3)] were higher in the hypercalcemic PHPT group than in the normal controls (all \( P < 0.001 \)). ALT (\( P = 0.757 \)) did not differ in the hypercalcemic PHPT group after adjusting for age and sex. There were no differences in DBP, AST, or potassium levels among the groups at baseline.

**Correlation between Cl/PO₄ or ALP levels and general parameters.** As shown in Tables 2 and 3, correlation analysis revealed that the Cl/PO₄ and ALP levels correlated with PTH and calcium in all of the subjects. Cl/PO₄ levels had positive associations with age (\( r = 0.134, P = 0.047 \)), PTH (\( r = 0.463, P < 0.001 \)), sodium (\( r = 0.202, P < 0.003 \)), and calcium (\( r = 0.586, P < 0.001 \)) and negative associations with BMI (\( r = -0.251, P < 0.001 \)) and Hb (\( r = -0.235, P < 0.001 \)). Simultaneously, the ALP level was positively associated with Cl/PO₄ (\( r = 0.357, P < 0.001 \)), PTH (\( r = 0.647, P < 0.001 \)), calcium (\( r = 0.58, P < 0.001 \)), and negatively associated with BMI (\( r = -0.141, P = 0.036 \)) and Hb (\( r = -0.307, P < 0.001 \)). To minimise confounding effects in different groups, additional analyses were performed. Cl/PO₄ and ALP levels were significantly positively associated with PTH, calcium in both groups.

**Baseline Cl/PO₄ and ALP Level Are Predictors of PHPT.** The stepwise multiple regression model was refined to assess the factors that were independently associated with PHPT (Table 4 and Table 5). Cl/PO₄ levels were an independent risk factor for hypercalcemia group of PHPT (odds ratio (OR): 0.832; 95% CI, 0.769–0.900; \( P < 0.001 \), after adjusting for age, sex, BMI, sodium, and Hb. To determine if calcium had a confounding effect, the same stepwise analysis was performed in the NPHPT subgroup. Cl/PO₄ levels were an independent risk factor for this group (odds ratio (OR): 0.797; 95% CI, 0.667–0.951; \( P = 0.012 \), after adjusting for some factors (Table 4). The ALP model also yielded results similar to the Cl/PO₄ model (Table 5). This result shows that the Cl/PO₄ and ALP levels were predictors of diagnosing PHPT.

**Predictive value of the Cl/PO₄ plus ALP model.** The receiver-operating characteristic curves shown in Fig. 1 represent the predictive value of different models for PHPT events in both groups. In the NPHPT group, the ROC-AUC was 0.743 (95% CI, 0.587–0.899) for Cl/PO₄ alone. However, Cl/PO₄ combined with the ALP model significantly increased the ROC-AUC (0.913; 95% CI, 0.744–1.000). Cl/PO₄ >33.07 (specificity = 80%, sensitivity = 73.7%), ALP >71.5 (specificity = 66%, sensitivity = 94.7%), the combination of Cl/PO₄ and ALP (specificity = 83%, sensitivity = 94%, positive predictive value = 53.1% and negative predictive value = 73.9%) can be used to predict diagnosing PHPT. In the hypercalcemia group of PHPT, the ROC-AUC of Cl/PO₄ alone was 0.897 (95% CI, 0.851–0.942), and increased significantly to 0.932 (95% CI, 0.897–0.966) when combined with ALP (Fig. 2). A high specificity of 80% and sensitivity of 88.9% were achieved at a Cl/PO₄ threshold of 33.05. A high specificity of 92% and sensitivity of 67.3% were achieved at a ALP threshold of 90.0. When Cl/PO₄ combined with ALP, specificity of 92.8%, sensitivity of 98%, positive predictive value of 51.4% and negative predictive...
value of 78.3% were achieved. These results show that Cl/PO4 combined with ALP might have better predictive value in both the NPHPT and hypercalcaemia groups.

**Discussion**

The estimated prevalence of PHPT increased by 0.07% in 2006 in a study conducted in Scotland\(^ {14} \) and by 0.09–0.23% in a study conducted in California, USA\(^ {15} \). The prevalence of PHPT fluctuates between 0.27% and 0.3% with increased laboratory testing\(^ {16} \). PHPT is more prevalent among postmenopausal women in China\(^ {17,18} \). The results presented here provide the first evidence that Cl/PO4 combined with ALP might increase the rate of diagnosis of PHPT in Chinese populations. This finding provides a new strategy for clinical practice. Currently, the diagnostic approach to PHPT is based mainly on serum calcium\(^ {19,20} \) and PTH\(^ {21,22} \), which has some limitations. There are no typical clinical manifestations in the early stages of PHPT, especially NPHPT, and in the diagnosis of gestational primary hyperparathyroidism (PHPT). The method used to measure intact PTH cannot be done in some hospitals, which likely causes misdiagnosis and delayed treatment. Clinicians need new screening tools to improve diagnostic accuracy.

Other auxiliary clinical indexes, such as alkaline phosphatase (ALP) levels, are increased in normocalcaemic PHPT patients\(^ {8,23} \). Boughey \textit{et al.}\(^ {3} \) analysed the data for 106 patients from South Carolina with PHPT and found that Cl/PO4 might help to confirm diagnoses of PHPT. It was useful for discriminating the cause of PHPT in

| Baseline Variables | Total Cohort | NPHPT | Hypercalcaemia group of PTPH |
|-------------------|-------------|-------|-----------------------------|
| Sex male (%)      | –0.074      | 0.275 | 0.193                       |
| Age (years)       | 0.134       | 0.047* | 0.115                       |
| BMI (kg/m²)       | –0.251      | <0.001* | 0.076                       |
| SBP (mmHg)        | 0.002       | 0.980 | 0.235                       |
| DBP (mmHg)        | 0.109       | 0.106 | 0.209                       |
| ALP (U/L)         | –0.325      | <0.001* | 0.167                       |
| ALT (U/L)         | –0.094      | 0.164 | 0.050                       |
| AST (U/L)         | –0.023      | 0.728 | –0.071                      |
| ALP (U/L)         | 0.357       | <0.001* | 0.274                       |
| PTH (ng/L)        | 0.463       | <0.001* | 0.407                       |
| Sodium (mmol/L)   | 0.202       | 0.003* | 0.251                       |
| Potassium (mmol/L)| –0.056      | 0.408 | –0.140                      |
| Calcium (mmol/L)  | 0.586       | <0.001* | 0.394                       |

**Table 2.** Correlations of the chloride/phosphorus ratio (Cl/PO₄) with other variables in subjects with PHPT. PHPT, primary hyperparathyroidism; NPHPT, normocalcaemic primary hyperparathyroidism; BMI, body mass index; SBP, systolic blood pressure; DBP, diastolic blood pressure; Hb, haemoglobin; ALT, alanine aminotransferase; AST, aspartate aminotransferase; ALP, alkaline phosphatase; PTH, parathyroid hormone.

#P < 0.05 vs. normal controls.

| Baseline Variables | Total Cohort | NPHPT | Hypercalcaemia group of PTPH |
|-------------------|-------------|-------|-----------------------------|
| Sex male (%)      | –0.126      | 0.06  | 0.087                       |
| Age (year)        | –0.019      | 0.78  | 0.242                       |
| BMI (kg/m²)       | –0.141      | 0.036* | 0.35                        |
| SBP (mmHg)        | 0.097       | 0.151 | 0.529                       |
| DBP (mmHg)        | 0.103       | 0.125 | 0.257                       |
| Hb                | –0.307      | <0.001* | 0.016                       |
| ALT (U/L)         | –0.029      | 0.663 | 0.169                       |
| AST (U/L)         | –0.02       | 0.765 | 0.121                       |
| Cl/PO4            | 0.357       | <0.001* | 0.274                       |
| PTH (ng/L)        | 0.647       | <0.001* | 0.623                       |
| Sodium (mmol/L)   | –0.034      | 0.609 | 0.244                       |
| Potassium (mmol/L)| –0.039      | 0.566 | 0.008                       |
| Calcium (mmol/L)  | 0.58        | <0.001* | 0.377                       |

**Table 3.** Correlations of ALP with other variables in subjects with PHPT. PHPT, primary hyperparathyroidism; NPHPT, normocalcaemic primary hyperparathyroidism; BMI, body mass index; SBP, systolic blood pressure; DBP, diastolic blood pressure; Hb, Hemoglobin; ALT, alanine aminotransferase; AST, aspartate aminotransferase; Cl/PO4, Chloride/phosphorus ratio; PTH, parathyroid hormone; ALP, Alkalinephosphatase.

#p < 0.05 vs. normal controls.
addition to PTH. The predictive value of Cl/PO4 < 33 for excluding the diagnosis was greater than 99%. Some studies have reported that serum ALP is positively associated with PTH in PHPT, and PTH significantly influenced the bone isoenzyme of ALP. Nasir et al. suggested ALP as a readily available marker to detect metabolic bone disorders. ALP levels were shown to be increased in PHPT patients, and serum ALP is a potential indicator for the occurrence of postoperative hypocalcemia in PHPT patients. Our findings which Cl/PO4 threshold > 33.07 and ALP > 71.5 in the NPHPT group, Cl/PO4 > 33.05 and ALP threshold of 90.0 in the hypercalcaemia group of PHPT were consistent with theirs, although there were some differences due to the different populations. We found that both Cl/PO4 and ALP might be helpful biochemical predictors of PHPT. Moreover, the combination model significantly increased the predicted value of PHPT in both groups. Therefore, our finding suggests that Cl/PO4 combined with ALP is an inexpensive screening tool for predicting PHPT without the costly PTH assays.

These findings provide important clues regarding the pathophysiological mechanism underlying the association between Cl/PO4 and PHPT. One possible explanation is that PTH decreases the tubular reabsorption of phosphate in the proximal renal tubule, which increases urinary phosphate and decreases serum phosphate. The reabsorption of bicarbonate from the proximal renal tubule is decreased by the action of PTH, causing the reabsorption of chloride and increasing the secretion of bicarbonate from the kidney. These findings may partly account for the observed association between serum Cl/PO4 and PHPT.

Previous studies suggested that elevated ALP levels existed in the patients of primary hyperparathyroidism. Serum alkaline phosphatase originated principally from bone. Elevated level of ALP is a marker of

### Table 4. Multivariate adjusted ORs (95% CI) of Cl/PO4 between PHPT and normal controls. aModel 1 was unadjusted. bModel 2 adjusted for age, sex, and BMI. cModel 3 adjusted for the covariate in model 2 plus sodium and Hb. dP < 0.05.

| Cl/PO4   | NPHPT         | P-value | Hypercalcaemia group of PHPT | P-value |
|----------|---------------|---------|------------------------------|---------|
| Model 1a | 0.878 (0.800–0.965) | 0.007*  | 0.834 (0.786–0.886)          | < 0.001* |
| Model 2b | 0.837 (0.735–0.952) | 0.007*  | 0.832 (0.780–0.887)          | < 0.001* |
| Model 3c | 0.797 (0.667–0.951) | 0.012*  | 0.832 (0.769–0.900)          | < 0.001* |

### Table 5. Multivariate adjusted ORs (95% CI) of ALP between PHPT and normal control. aModel 1 was unadjusted. bModel 2 included age, sex and BMI for adjustment. cModel 3 included the covariate in model 2 plus Hb for adjustment. dP < 0.05.

| ALP     | NPHPT         | P-value | Hypercalcaemia group of PHPT | P-value |
|---------|---------------|---------|------------------------------|---------|
| Model 1a | 0.945 (0.913–0.978) | 0.001*  | 0.960 (0.944–0.976)          | < 0.001* |
| Model 2b | 0.940 (0.886–0.997) | 0.041*  | 0.959 (0.938–0.979)          | < 0.001* |
| Model 3c | 0.929 (0.866–0.986) | 0.043*  | 0.958 (0.936–0.979)          | < 0.001* |
osteoblast activity increase. Bone metabolism is a dynamic balance of the process by common regulation of bone resorption and bone formation. Although osteoclasts are the primary target organ for PTH to accelerate bone resorption and destruction, functional PTH receptors were expressed in both osteoblasts and osteoclasts. When PTH combined with its receptors, they could indirectly stimulate effect mediated by osteoblasts. Due to bone formation and bone resorption processes coupling in bone remodeling units, osteoblast activity also increased in PHTP with the increase in osteoblast activity. Osteoblasts responded to PTH with an increase in ALP as bone morphogenetic marker. Additionally, as the research was observing this trend of ALP slight elevation currently, the further studies including more samples should be performed. So in clinical work, when we found that ALP was close to upper limit of the normal range or higher than normal range, we need to further detect other laboratory indicators of PHPT so that they could increase the predicted value of PHTP.

The above findings may partly account for the observed association among serum Cl/PO4, ALP and PHPT. Simultaneously, in the study, we found significant difference of Hb and sodium between patients with hyperparathyroidism and normal, but there was no significant difference after adjusting for Hb and sodium. On the one hand, the pathophysiological mechanism of elevated Hb in PHPT patients has not yet known. On the other hand, as for serum sodium level was different in two groups, one possible pathophysiological mechanism was that patients with hyperparathyroidism have higher aldosterone levels, and elevated aldosterone levels have positive correlation with sodium intake. Another possible pathophysiological mechanism was that the reabsorption of sodium was induced by PTH. Further research is needed to clarify the potential pathophysiological mechanism. This study had several limitations. First, the age and sex of control group were not very match up to the PHPT group, so we performed the analysis adjusting for age and sex in each step to eliminate the bias from age and sex. Second, a small sample size from a single centre cannot fully reflect the entire Chinese population. The study was based on parathyroid adenoma of PHPT. Further prospective studies that include parathyroid carcinoma and parathyroid hyperplasia cases should be performed. Additionally, we have analysed the patients of PTH-dependent hypercalcemia in the study. Whether the chloride/phosphate ratio combined with alkaline phosphatase as a valuable predictive marker for PTH-independent hypercalcemia, further study is urged to for certification. Third, given the cross-sectional design of the study, the most important limitation is a lack of causation. Therefore, follow-up studies should be prospective and include a large number of cases to confirm our findings.

In conclusion, we revealed an association among Cl/PO4, ALP and PHPT, especially NPHPT, in Chinese individuals. Due to its low cost and availability, Cl/PO4 could increase the rate of diagnosis of PHPT, particularly NPHPT, when combined with ALP. The clinical significance of this model should be corroborated in larger studies.

References
1. Wills, M. R. et al. Normocalcemic Primary hyperparathyroidism. Am J Med 47, 384–391 (1967).
2. Cusano, N. E., Silverberg, S. J. & Bilezikian, J. P. Normocalcemic primary hyperparathyroidism. J Clin Densitom 16, 33–39 (2013).
3. Velez, R. P., Donnelly-Stroozo, M. & Stanik-Hutt, J. Simplifying the Complexity of Primary Hyperparathyroidism. The Journal for Nurse Practitioners 12, 346–352 (2016).
4. Maruani, G. H. et al. Normocalcemic primary hyperparathyroidism: evidence for a generalized target-tissue resistance to parathyroid hormone. J Clin Endocrinol Metab 88, 4641–4648 (2003).
5. Cadilo, G. et al. Oral calcium tolerance test in the early diagnosis. Gut 39, 273–278 (1996).
6. Reeves, C. D. et al. Differential diagnosis of hypercalcemia by the chloride phosphate ratio. The American Journal of Surgery 130, 166–171 (1975).
7. Wong, E. T. & Freier, E. F. The differential diagnosis of hypercalcemia. An algorithm for more effective use of laboratory tests. JAMA 247, 75–80 (1982).
8. Boughhey, J. C. et al. Chloride phosphate ratio in primary hyperparathyroidism. The American Surgeon 70, 25–28 (2004).
9. McComb, R. M. Bowers, G. N. Posen, S. Alkaline Phosphatase. Springer, 25 (2011).
10. Broulik, P. D. & Pacovsky, V. The chloride phosphate ratio as the screening test for primary hyperparathyroidism. *Horm Metab Res* **11**, 577–579 (1979).

11. Mismar, A. A. *et al.* Performance of chloride phosphate test in patients with primary hyperparathyroidism. *Is it related to calcium level*. *Saudi Med J* **34**, 801–805 (2013).

12. Stefková, K., Procházková, J. & Pachernik, J. Alkaline Phosphatase in. *Stem Cells. Stem Cells International* **2015**, 1–11 (2015).

13. Stepan, J. J. *et al.* Relationship phosphate of plasma tartrate resistant acid to the bone isoenzyme of serum alkaline phosphatase in hyperparathyroidism. *Clinica Chimica Acta* **133**, 189–200 (1983).

14. Ying, Y., Donnan, P. T. & Leese, G. P. A record linkage study of outcomes in patients with mild primary hyperparathyroidism: The Parathyroid Epidemiology and Audit Research Study (PEARS). *Clinical Endocrinology (Oxf)* **75**, 169–176 (2011).

15. Yeh, M. W. *et al.* Incidence and prevalence of primary hyperparathyroidism in a racially mixed population. *J Clin Endocrinol Metab* **98**, 1122–1129 (2013).

16. Qing, L. *et al.* The key role of 99mTc-MIBI SPECT/CT in the diagnosis of parathyroid adenoma: a case report. *Arch. Endocrinol Metab* **59**, 265–269 (2015).

17. Fraser, W. D. Hyperparathyroidism. *Lancet* **374**, 145–158 (2009).

18. James, H., Thompson, G. B., Wermers, R. A. Primary Hyperparathyroidism in Pregnancy [M]//Hyperparathyroidism. Springer International Publishing 129–135 (2016).

19. Bilezikian, J. P. Primary Hyperparathyroidism. Endotext, 2000.

20. Gregory, R., Mundy, D. C. & Fisken, R. Primary hyperparathyroidism: changes in the pattern of clinical presentation. *Lancet* **315**, 1317–1320 (1980).

21. Bilezikian, J. P. *et al.* Summary statement from a workshop on asymptomatic primary hyperparathyroidism: a perspective for the 21st century. *J Clin Endocrinol Metab* **87**, 3533–3561 (2002).

22. Berger, C. *et al.* Characteristics of hyperparathyroid states in the Canadian multicentre osteoporosis study (CaMos) and relationship to skeletal markers. *Clin Endocrinol (Oxf)* **82**, 359–368 (2014).

23. Sun, L. *et al.* Preoperative serum alkaline phosphatase: a predictive factor for early hypocalcaemia following parathyroidectomy of primary hyperparathyroidism. *Clin Med (Engl)* **127**, 3259–3264 (2014).

24. Fogelman, I. *et al.* Estimation of skeletal involvement in primary hyperparathyroidism. Use of 24-hour whole-body retention of technetium-99m diphosphonate. *Ann Intern Med** **92**, 65–67 (1980).

25. Nasir, A. M. *et al.* Alkaline Phosphatase (ALP) Activity as a marker for Vitamin D deficiency. *American Journal of Research Communication* **3**, 1–9 (2015).

26. Puschet, J. B. Renal tubular effects of parathyroid hormone an update. *Bone* **33**, 249–259 (1978).

27. Yu, T. D. *et al.* New insights into the effects of primary hyperparathyroidism on the cortical and trabecular compartments of bone. *Bone* **55**, 57–63 (2013).

28. Dempster, D. W. *et al.* Anabolic actions of parathyroid hormone on bone. *Endocrine reviews* **14**, 690–709 (1993).

29. Bellido, T., Saini, V. & Pajevic, P. D. Effects of PTH on osteocyte function. *Bone* **54**, 250–257 (2013).

30. Park-Sigal, J. *et al.* Severe hypercalcemia hyperparathyroidism developing in a patient with hyperaldosteronism and renal resistance to parathyroid hormone. *Journal of Bone and Mineral Research** **28**, 700–708 (2013).

Acknowledgements

The authors would like to thank for providing in ALP and PTH measurements, and all the participants in the General Surgery Department and clinical check-ups of Shanghai Jiao Tong University Affiliated Sixth People’s Hospital. This study was supported by grants from the Natural Science Foundation of China (81370956 and 81570778).

Author Contributions

H.J.F and W.L. designed the study. W.Q.Q. analysed the data and wrote a draft of this manuscript. L.X. collected blood samples and data. C.H.B., Y.H.Y. and L.L.X. performed statistical analysis and assisted with recruiting patients. Y.J., Z.J., L.M. and L.Q. revised the draft manuscript. B.Y.Q., L.F. and J.W.P. contributed to the design of the study. All authors gave approval for the final version of this manuscript.

Additional Information

Competing Interests: The authors declare that they have no competing interests.

Publisher’s note: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

© The Author(s) 2017